Clinical Follow-up Study of Methimazole Treatment in Adults with Newly Diagnosed or Relapsed Graves Disease

What this Trial Is About

Researchers are conducting a long-term follow-up study of adults with newly diagnosed or relapsed Graves disease at the First Affiliated Hospital of China Medical University. The study aims to determine relapse and remission rates after drug treatment, identify risk factors for relapse, evaluate the effects and side effects of different doses of methimazole, and investigate the diagnostic and predictive value of TRAb. They also analyze changes in serum alkaline phosphatase related to methimazole treatment and thyroid function. Participants receive methimazole treatment with dosages adjusted according to established guidelines. During outpatient follow-ups, thyroid and liver function tests, TRAb levels, and blood counts are performed to monitor treatment effects and side effects such as liver injury and leukopenia. The study assesses the sensitivity and specificity of TRAb in diagnosis and recurrence prediction, and tracks biochemical changes over time. Over a period of up to 30 years, participants will be regularly monitored through clinical evaluations and laboratory tests to assess their disease status, treatment outcomes, and adverse effects. The research team will collect data on relapse, remission, and drug safety to develop risk prediction tools and better understand Graves disease management. The study includes long-term observation and safety monitoring throughout the follow-up.

A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China